David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target is ...

Investing.com - Shares of biopharmaceutical firm Apellis Pharmaceuticals Inc (NASDAQ: APLS) surged 16.44% to $31 on Tuesday ...

Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 18, ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

Although some pharma companies are trying to improve drug access in low- and middle-income countries, the progress overall is ...

Weight-loss drugs promise to make the pounds melt away, and beauty products and fillers will erase those fine lines. But do you know what you're getting or where it's coming from?

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...

For Esperion Therapeutics, 2024 has marked a pivotal transformation in its mission to combat cardiovascular disease. | ...